Antibody for binding to interleukin 4 receptor
AssigneeSuzhou Connect Biopharmaceuticals, Ltd.
InventorsWei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
Life of this patent
Estimating the term…
Abstract
Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
Claims25
An isolated anti-interleukin 4 receptor (IL-4R) antibody comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein the isolated antibody exhibits at least a 2-fold higher area under the drug-time curve as compared to a control antibody comprising a light chain variable region sequence as set forth in SEQ ID NO:
- 58 and a heavy chain variable region sequence as set forth in SEQ ID NO:
- 93.
An isolated nucleic acid or set of nucleic acids encoding an isolated anti-interleukin 4 receptor (IL-4R) antibody comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein the isolated antibody exhibits a 2-fold higher area under the drug-time curve as compared to a control antibody comprising a light chain variable region sequence as set forth in SEQ ID NO:
- 58 and a heavy chain variable region sequence as set forth in SEQ ID NO:
- 93.
A method of preventing, treating, or ameliorating inflammation or allergic disease in a subject in need thereof, comprising administering to the subject an isolated anti-IL-4R antibody comprising a variable heavy (VH) chain sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and a variable light (VL) chain sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein the isolated antibody exhibits at least a 2-fold higher area under the drug-time curve as compared to a control antibody comprising a light chain variable region sequence as set forth in SEQ ID NO:
- 58 and a heavy chain variable region sequence as set forth in SEQ ID NO:
- 93.
Dependencies are inferred from the claim text.